These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
640 related articles for article (PubMed ID: 33381312)
41. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987 [TBL] [Abstract][Full Text] [Related]
42. Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference? Cascales-Campos P; López-López V; Gil J; Arévalo-Pérez J; Nieto A; Barceló F; Gil E; Parrilla P Surg Oncol; 2016 Sep; 25(3):164-70. PubMed ID: 27566018 [TBL] [Abstract][Full Text] [Related]
43. A phase 2 trial of short-course Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) at interval cytoreductive surgery (iCRS) for advanced ovarian cancer. Batista TP; Carneiro VCG; Tancredi R; Badiglian Filho L; Rangel RLC; Lopes A; Sarmento BJQ; Leão CS Rev Col Bras Cir; 2022; 49():e20223135. PubMed ID: 35239855 [TBL] [Abstract][Full Text] [Related]
44. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746 [TBL] [Abstract][Full Text] [Related]
45. Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival with Acceptable Safety for Advanced Ovarian Cancer: A Clinical Study of 100 Patients. Zhang J; Li XB; Ji ZH; Ma R; Bai WP; Li Y Biomed Res Int; 2021; 2021():5533134. PubMed ID: 34258265 [TBL] [Abstract][Full Text] [Related]
46. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450 [TBL] [Abstract][Full Text] [Related]
47. Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer. Brault C; Brind'Amour A; de Guerke L; Auclair MH; Sideris L; Dubé P; Soucisse M; Tremblay JF; Bernard L; Piedimonte S; Fortin S Curr Oncol; 2023 Dec; 30(12):10272-10282. PubMed ID: 38132382 [TBL] [Abstract][Full Text] [Related]
48. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Aronson SL; Lopez-Yurda M; Koole SN; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van Gent MDJM; Arts HJG; van Ham MAPC; van Dam PA; Vuylsteke P; Aalbers AGJ; Verwaal VJ; Van de Vijver KK; Aaronson NK; Sonke GS; van Driel WJ Lancet Oncol; 2023 Oct; 24(10):1109-1118. PubMed ID: 37708912 [TBL] [Abstract][Full Text] [Related]
49. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center. Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715 [TBL] [Abstract][Full Text] [Related]
50. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884 [TBL] [Abstract][Full Text] [Related]
51. Perioperative intraperitoneal plus systemic chemotherapy and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for gastric cancer: phase Ib/II single-arm prospective study. Cho M; Kim HS; Jung M; Hyung WJ J Gastrointest Surg; 2024 Jul; 28(7):1095-1103. PubMed ID: 38705369 [TBL] [Abstract][Full Text] [Related]
52. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239 [TBL] [Abstract][Full Text] [Related]
53. Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients. Paquette B; Kalbacher E; Mercier F; Lakkis Z; Doussot A; Turco C; Caputo E; Pili-Floury S; Royer B; Mansi L; Delroeux D; Demarchi M; Pivot X; Chauffert B; Clement E; Heyd B Ann Surg Oncol; 2022 May; 29(5):3322-3334. PubMed ID: 34994906 [TBL] [Abstract][Full Text] [Related]
54. Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial. Ferron G; De Rauglaudre G; Becourt S; Delanoy N; Joly F; Lortholary A; You B; Bouchaert P; Malaurie E; Gouy S; Kaminsky MC; Meunier J; Alexandre J; Berton D; Dohollou N; Dubot C; Floquet A; Favier L; Venat-Bouvet L; Fabbro M; Louvet C; Lotz JP; Abadie-Lacourtoisie S; Desauw C; Del Piano F; Leheurteur M; Bonichon-Lamichhane N; Rastkhah M; Follana P; Gantzer J; Ray-Coquard I; Pujade-Lauraine E Gynecol Oncol; 2023 Mar; 170():186-194. PubMed ID: 36706645 [TBL] [Abstract][Full Text] [Related]
55. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer. Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409 [TBL] [Abstract][Full Text] [Related]
56. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer. Koole SN; Kieffer JM; K Sikorska ; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham MAPC; Aalbers AG; Verwaal VJ; Van de Vijver KK; Sonke GS; van Driel WJ; Aaronson NK Eur J Surg Oncol; 2021 Jan; 47(1):101-107. PubMed ID: 31128948 [TBL] [Abstract][Full Text] [Related]
57. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Bian C; Yao K; Li L; Yi T; Zhao X Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168 [TBL] [Abstract][Full Text] [Related]
58. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness. da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355 [TBL] [Abstract][Full Text] [Related]
59. Patterns of pathological response to neoadjuvant chemotherapy and its clinical implications in patients undergoing interval cytoreductive surgery for advanced serous epithelial ovarian cancer- A study by the Indian Network for Development of Peritoneal Surface Oncology (INDEPSO). Bhatt A; Sinukumar S; Mehta S; Damodaran D; Zaveri S; Kammar P; Mishra S; Parikh L; Ranade R; Penumadu P; Rajan F Eur J Surg Oncol; 2019 Apr; 45(4):666-671. PubMed ID: 30661922 [TBL] [Abstract][Full Text] [Related]
60. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy. Zhou S; Jiang Y; Liang J; Pei W; Zhou Z World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]